Printer Friendly

FDA ADVISORY PANEL RECOMMENDS USE OF MERCK'S PRINIVIL(R) FOR HEART FAILURE

 WEST POINT, Pa., Feb. 18 /PRNewswire/ -- An advisory committee of the Food and Drug Administration today recommended use of Merck's (NYSE: MRK) ACE inhibitor Prinivil(R) (lisinopril) as once-daily adjunctive therapy with diuretics and digitalis for the treatment of heart failure. Since its introduction in 1987, Prinivil has been indicated for the treatment of hypertension.
 In long-term clinical trials, the use of Prinivil in patients with heart failure receiving digitalis and diuretics resulted in greater improvement in exercise capacity, left ventricular systolic performance, signs and symptoms of heart failure and quality of life when compared to placebo.
 Prinivil has been generally well tolerated in patients with heart failure. In these patients, the most frequent clinical adverse experiences are dizziness, dyspnea, chest pain, asthenia, cough, diarrhea, and hypotension.
 Merck is a worldwide, research-intensive health products company that discovers, develops, produces and markets human and animal health products and specialty chemicals.
 NOTE: The recommendation(s) of the Advisory Committee do not indicate final FDA approval.
 /delval/
 -0- 2/18/93
 /CONTACT: Gary M. Bruell, 215-652-7485, or, home, 215-368-7328; or Michael Seggev, 215-652-6931, or, home, 215-361-1594, both of Merck/
 (MRK)


CO: Merck & Co., Inc.; U.S. Food and Drug Administration ST: Pennsylvania IN: MTC SU:

CC -- PH044 -- 8035 02/18/93 15:39 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 18, 1993
Words:211
Previous Article:MERIDIAN DAYS OF HOPE CALENDAR RAISES $115,000 FOR AREA HOMELESS
Next Article:KNOWLEDGWARE COMPLETES ACQUISITION OF MATESYS CORP.; OBJECTVIEW A KEY COMPONENT OF KNOWLEDGEWARE'S CLIENT/SERVER PORTFOLIO
Topics:


Related Articles
FDA PANEL RECOMMENDS CAPOTEN(R) FOR POST-HEART ATTACK PATIENTS
FDA ADVISORY PANEL RECOMMENDS USE OF MERCK'S PRINIVIL(R) FOR HEART FAILURE
FDA ADVISORY PANEL RECOMMENDS USE OF MERCK'S VASOTEC(R) FOR BROADENED HEART FAILURE USE
FDA ADVISORY PANEL RECOMMENDS USE OF MERCK'S VASOTEC(R) FOR BROADENED HEART FAILURE USE
FDA panel recommends that Sanofi-Aventis antibiotic Ketek should not be marketed for sinusitis or bronchitis.
FDA advisers reject Merck's newest COX-2.
FDA panel rejects OTC switch for lovastatin.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters